The US pharmacist reported that this efficacy was achieved seven days after the second dose of vaccine and 28 days after the first. It is tested in Argentina.
Pharmaceutical Pfizer said Monday that its coronavirus vaccine is “90% effective“, according to the first interim analysis of its phase 3 trial, the last stage before formally requesting its homologation.
This protective efficacy against the SARS-CoV-2 virus was achieved seven days after the second dose of vaccine and 28 days after the first, the US pharmaceutical company indicated in a joint statement with BioNTech.
The data is more than optimistic since scientists expect an effectiveness of around 75%.
Argentina is one of the countries in which the Pfizer vaccine tests are carried out. About 4500 volunteers received the two doses and it was was “very well tolerated by all participants“.
Albert Bourla, president and CEO of Pfizer, hailed the development as a “great day for science and humanity.”
The analysis evaluated 94 confirmed Covid-19 infections among 43,538 trial participants. Pfizer and BioNTech stated that the division of cases between vaccinated people and those who received a placebo indicated a vaccine efficacy rate greater than 90% seven days after the second dose.
“Efficacy in the majority of participants, safety data, and consistent manufacturing are the three requirements that are needed before you can apply for emergency use authorization,” the pharmacist said.
Based on projections, both companies stated that they plan to supply 50 million doses worldwide in 2020 and up to 1.3 billion in 2021.
After knowing the news, the main European stock markets showed increases of more than 1%.
Madrid rose 9.32%; Paris, 5.42%; Milan, 4.83%, Frankfurt, 4.77% and London 4.49%, while the Eurostoxx50 index of the 50 largest capitalization companies increased 5.20% at 1:20 p.m.
With information from AFP.